Eli Lilly will offer Guidant stake as split-off:
This article was originally published in Clinica
Executive Summary
Eli Lilly's disposal of its 82%-stake in Guidant will take the form of a split-off - an offer to Lilly shareholders to exchange some or all of their Lilly stock for Guidant shares. This plan had been one of the options outlined when Lilly announced its exit from the medical devices industry in January 1994. The split-off proposal is contained in a registration statement filed with the US Securities and Exchange Commission. Following review by the SEC and depending on market conditions, Guidant expects the split-off to be completed during the autumn this year. Specific terms will be announced at the commencement of the exchange offer, the company adds.
You may also be interested in...
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.